Arcus Biosciences, Inc.
RCUSHealthcareNASDAQBiotechnology
Scan Results
Daily timeframeArcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. At a $3.73B market cap, Arcus Biosciences, Inc. ranks as a mid-cap company within healthcare. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody.
Market Cap
$3.73B
Beta
0.81
P/E (TTM)
—
P/E (Fwd)
-8.88
EPS (TTM)
$-3.94
EPS (Fwd)
$-3.34
ROE
-90.8%
ROA
-30.4%
Cash
$702.0M
Total Debt
$238.0M
Free CF
-$270.6M
52W Change
162.0%
Annual Financials
Cash vs Debt
Where RCUS stands vs its 150-day and 200-day moving averages
As of the September 3, 2026 close, RCUS finished 19.26% above its 150-day moving average ($25.03) and 21.74% above its 200-day moving average ($24.52). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is RCUS overbought or oversold?
At the September 3, 2026 close, RCUS's RSI(14) was 56.3, in neutral territory (between 30 and 70). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $702.0M in cash and $238.0M in debt, RCUS maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. The company is burning cash, with free cash flow at -$270.6M. This typically occurs when a company is investing aggressively in growth, but sustained cash burn can strain the balance sheet. Return on equity stands at -90.8%, which is negative for the sector. ROE measures how effectively a company uses shareholder capital to generate profits. Revenue has grown from $112.0M (2022) to $247.0M (2025), reflecting a 121% increase over the period.
With cash comfortably exceeding debt, RCUS has financial flexibility that may help navigate uncertain periods. The company is burning cash at the operating level, which is not unusual for growth-phase companies but adds risk if it persists. It is important to consider these factors alongside broader market conditions and individual financial goals when reviewing RCUS.